Phase II B Trial – Talk Bio

Enanta Presses Ahead with RSV Drug Zelicapavir Despite Missing Primary Endpoint in Phase IIb Trial

4 weeks ago talkbio0Tagged Clinical Trials, Congestive heart failure, COPD, development aspects, Elderly (population group), Enanta, Hospitalization, Neoplasm Metastasis, Phase II B Trial, primary endpoint, rates, Respiratory syncytial virus, United States Food and Drug Administration, Zelicapavir

Enanta Pharmaceuticals; RSV; zelicapavir; Phase IIb trial; primary endpoint miss; secondary endpoints; clinical trials; FDA Fast Track; elderly; COPD; congestive heart failure; hospitalization rates; future development

Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical

4 months ago talkbio0Tagged analysts, Clinical Trials, Dermatitis, Atopic, Dupixent, EASI, Eczema, Lilly partnership, Nektar Therapeutics, Phase II B Trial, Rezpeg, Rezpegaldesleukin, Score, Skepticism

Nektar Therapeutics; Rezpegaldesleukin; Rezpeg; Phase IIb trial; eczema; atopic dermatitis; clinical trial; EASI score; Dupixent; analyst skepticism; Lilly partnership